Dashenlin Pharm Grp Co Ltd Total Liabilities
Dashenlin Pharm Grp Co Ltd total liabilities. Based on the latest financial reports, Dashenlin Pharm Grp Co Ltd (603233) has total liabilities worth CN¥17.65 Billion CNY (≈ $2.58 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Dashenlin Pharm Grp Co Ltd to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Dashenlin Pharm Grp Co Ltd (2012–2025)
Total liabilities of Dashenlin Pharm Grp Co Ltd from 2012 to 2025. This chart illustrates how Dashenlin Pharm Grp Co Ltd's total liabilities have evolved over time, based on quarterly financial data.
Dashenlin Pharm Grp Co Ltd Competitors by Total Liabilities
The table below lists competitors of Dashenlin Pharm Grp Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kimberly-Clark de México S. A. B. de C. V
MX:KIMBERA
|
Mexico | MX$43.60 Billion |
|
TUI AG
XETRA:TUI1
|
Germany | €14.08 Billion |
|
Brickworks Ltd
AU:BKW
|
Australia | AU$2.45 Billion |
|
Sacyr SA
MC:SCYR
|
Spain | €16.55 Billion |
|
First Capital Securities Co Ltd Class A
SHE:002797
|
China | CN¥37.27 Billion |
|
RXO Inc.
NYSE:RXO
|
USA | $1.95 Million |
|
China Coal Xinji Energy Co Ltd
SHG:601918
|
China | CN¥36.90 Billion |
|
Peyto Exploration&Development Corp
TO:PEY
|
Canada | CA$2.49 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Dashenlin Pharm Grp Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 603233 total asset value.
Liquidity & Leverage Metrics
Dashenlin Pharm Grp Co Ltd Total Liabilities Ratios Explained
Dashenlin Pharm Grp Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.66 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dashenlin Pharm Grp Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dashenlin Pharm Grp Co Ltd (2012–2025)
The table below shows the annual total liabilities of Dashenlin Pharm Grp Co Ltd from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥17.83 Billion ≈ $2.61 Billion |
-2.60% |
| 2024-12-31 | CN¥18.30 Billion ≈ $2.68 Billion |
+13.04% |
| 2023-12-31 | CN¥16.19 Billion ≈ $2.37 Billion |
+15.83% |
| 2022-12-31 | CN¥13.98 Billion ≈ $2.05 Billion |
+22.61% |
| 2021-12-31 | CN¥11.40 Billion ≈ $1.67 Billion |
+68.66% |
| 2020-12-31 | CN¥6.76 Billion ≈ $989.06 Million |
+55.73% |
| 2019-12-31 | CN¥4.34 Billion ≈ $635.11 Million |
+25.79% |
| 2018-12-31 | CN¥3.45 Billion ≈ $504.89 Million |
+14.25% |
| 2017-12-31 | CN¥3.02 Billion ≈ $441.93 Million |
+34.94% |
| 2016-12-31 | CN¥2.24 Billion ≈ $327.50 Million |
+36.70% |
| 2015-12-31 | CN¥1.64 Billion ≈ $239.58 Million |
-8.55% |
| 2014-12-31 | CN¥1.79 Billion ≈ $261.98 Million |
+64.11% |
| 2013-12-31 | CN¥1.09 Billion ≈ $159.64 Million |
+77.27% |
| 2012-12-31 | CN¥615.39 Million ≈ $90.05 Million |
-- |
About Dashenlin Pharm Grp Co Ltd
DaShenLin Pharmaceutical Group Co., Ltd. engages in the manufacture, distribution, and retail of pharmaceutical products in China. It offers Chinese and Western patent medicines, ginseng and tonic herbs, Chinese herbal medicine slices, health products, medical devices, and other commodities. The company was incorporated in 1999 and is based in Guangzhou, China.